These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38760047)

  • 41. A nomogram to predict cadmium-induced renal tubular dysfunction.
    Wang X; Chen X; He W; Zhu G; Jin T; Chen X
    Sci Rep; 2020 Jun; 10(1):10121. PubMed ID: 32572089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preoperative renal function and surgical outcomes in patients with acute type A aortic dissection†.
    Imasaka K; Tayama E; Tomita Y
    Interact Cardiovasc Thorac Surg; 2015 Apr; 20(4):470-6. PubMed ID: 25535177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
    Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
    JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.
    Tiu BC; Strohbehn IA; Zhao S; Ouyang T; Hanna P; Wang Q; Gupta S; Leaf DE; Reynolds KL; Sise ME
    Oncologist; 2023 Jun; 28(6):e379-e390. PubMed ID: 36821637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Construction and validation of a machine learning-based nomogram: A tool to predict the risk of getting severe coronavirus disease 2019 (COVID-19).
    Yao Z; Zheng X; Zheng Z; Wu K; Zheng J
    Immun Inflamm Dis; 2021 Jun; 9(2):595-607. PubMed ID: 33713584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and Validation of a Nomogram for Predicting Incidence of Early Allograft Dysfunction Following Liver Transplantation.
    Yang L; Xin EY; Liao B; Lai LJ; Han M; Wang XP; Ju WQ; Wang DP; Guo ZY; He XS
    Transplant Proc; 2017; 49(6):1357-1363. PubMed ID: 28736007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and Cross-Validation of a Nomogram for Chronic Kidney Disease Following Robot-Assisted Radical Cystectomy.
    Elsayed AS; Jing Z; Demirbas D; Durrani M; Attwood K; Cilento J; Osei JA; Gibson S; Mostowy M; Christophe A; Hussein AA; Guru KA
    J Endourol; 2020 Sep; 34(9):946-954. PubMed ID: 32631086
    [No Abstract]   [Full Text] [Related]  

  • 49. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
    Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
    Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
    Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
    Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radiomics-based prediction of response to immune checkpoint inhibitor treatment for solid cancers using computed tomography: a real-world study of two centers.
    Yu Y; Bai Y; Zheng P; Wang N; Deng X; Ma H; Yu R; Ma C; Liu P; Xie Y; Wang C; Chen H
    BMC Cancer; 2022 Nov; 22(1):1241. PubMed ID: 36451109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.
    Heilbroner SP; Few R; Mueller J; Chalwa J; Charest F; Suryadevara S; Kratt C; Gomez-Caminero A; Dreyfus B; Neilan TG
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study.
    Cai Q; Wu W; Li R; Li X; Xu Q; Zhao L; Lv Q
    Int Immunopharmacol; 2024 Jan; 127():111337. PubMed ID: 38064811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
    Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Risk factor and nomogram for predicting the probability of a permanent stoma after laparoscopic intersphincteric resection for ultralow rectal cancer].
    Hu G; Liu JG; Qiu WL; Mei SW; Wang X; Tang JQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Nov; 25(11):997-1004. PubMed ID: 36396375
    [No Abstract]   [Full Text] [Related]  

  • 58. Development and validation of a nomogram to predict postoperative cancer-specific survival of patients with nonmetastatic T3a renal cell carcinoma.
    Guo P; Wang Y; Han Y; Wei D; Zhao J; Li M; Jiang Y; Luo Y
    Urol Oncol; 2021 Dec; 39(12):835.e19-835.e27. PubMed ID: 34620554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
    Chao Y; Zhou J; Hsu S; Ding N; Li J; Zhang Y; Xu X; Tang X; Wei T; Zhu Z; Chu Q; Neal JW; Wu JT; Song Y; Hu J
    Transl Lung Cancer Res; 2022 Feb; 11(2):295-306. PubMed ID: 35280322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.